Annexon (NASDAQ:ANNX) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Annexon (NASDAQ:ANNX) in a report issued on Monday, Benzinga reports.

A number of other equities research analysts also recently issued reports on ANNX. Needham & Company LLC restated a buy rating and set a $16.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Wells Fargo & Company decreased their price objective on Annexon from $12.00 to $10.00 and set an overweight rating on the stock in a research report on Wednesday, May 15th. Finally, HC Wainwright restated a buy rating and set a $30.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of Buy and a consensus target price of $15.80.

Annexon Trading Down 1.1 %

Shares of Annexon stock opened at $6.18 on Monday. Annexon has a 12 month low of $1.57 and a 12 month high of $8.40. The stock has a 50 day moving average of $5.76 and a 200 day moving average of $5.50. The firm has a market cap of $571.11 million, a PE ratio of -4.20 and a beta of 1.28.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.23). As a group, equities research analysts forecast that Annexon will post -0.97 earnings per share for the current fiscal year.

Insider Transactions at Annexon

In other news, EVP Ted Yednock sold 5,500 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $5.64, for a total value of $31,020.00. Following the sale, the executive vice president now directly owns 10,000 shares in the company, valued at $56,400. The sale was disclosed in a document filed with the SEC, which is available at this link. Over the last three months, insiders have acquired 9,600 shares of company stock worth $53,504 and have sold 12,888 shares worth $75,122. Company insiders own 12.67% of the company’s stock.

Institutional Investors Weigh In On Annexon

Hedge funds and other institutional investors have recently modified their holdings of the business. Ameritas Investment Partners Inc. increased its holdings in Annexon by 78.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock worth $48,000 after purchasing an additional 2,949 shares during the period. Comerica Bank purchased a new position in Annexon during the 1st quarter worth $72,000. Sandia Investment Management LP purchased a new position in Annexon during the 2nd quarter worth $49,000. Victory Capital Management Inc. purchased a new position in Annexon during the 2nd quarter worth $51,000. Finally, Principal Financial Group Inc. purchased a new position in Annexon during the 2nd quarter worth $56,000.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.